(Q38792697)

English

Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial

scientific article published on 09 May 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial (English)

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

central retinal vein occlusion

1 reference

based on heuristic

inferred from title

Ingrid U. Scott

1

object named as

Ingrid U Scott

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Barbara A. Blodi

4

object named as

Barbara A Blodi

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

3

object named as

Michael S Ip

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

author name string

Paul C VanVeldhuisen

2

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Neal L Oden

5

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Carl C Awh

6

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Derek Y Kunimoto

7

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Dennis M Marcus

8

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

John J Wroblewski

9

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Jacqueline King

10

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

SCORE2 Investigator Group

11

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

language of work or name

0 references

publication date

9 May 2017

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

The Journal of the American Medical Association

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

317

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

20

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

2072-2087

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Association of compounded bevacizumab with postinjection endophthalmitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

SCORE Study report 3: study design and baseline characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

23 June 2018

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

31 August 2018

VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

31 August 2018

Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

31 August 2018

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

31 August 2018

Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

31 August 2018

Visual acuity as an outcome measure in clinical trials of retinal diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

31 August 2018

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

31 August 2018

Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5710547

3 December 2018

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28492910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/28492910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMA.2017.4568

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 January 2018

http://europepmc.org/abstract/PMC/5710547

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38792697&oldid=1786960613"